

I hereby certify that this correspondence is being deposited with the United States Pastal Service as first-class mail in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313,1450 on this day of March 2004.

By

(Signature of person mailing)

Andrea E. Dorigo

Reg. No. 47,532
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Fossa, Anthony A.

Examiner:

APPLICATION NO.: 09/834,477

Group Art Unit: 1646

FILING DATE: 04/13/2001

TITLE: COMBINATION OF CORTICOTROPIN RELEASING

FACTOR ANTAGONISTS AND GROWTH

HORMONE SECRETAGOGUES

Mail Stop

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

<u>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u> PURSUANT TO 37 C.F.R. § 1.97 ET SEO.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references citd by the applicant(s).

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). The listing of the references on the PTO-FB-A820 form is not intended to represent or imply that these references are prior art to the above-captioned application. Applicants reserve the right to challenge the status of any reference so listed or otherwise identified as prior art.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445, including all fees required under 37 C.F.R. 1.97.

A prompt and favorable response is earnestly solicited.

Date: $\frac{2}{3}$

Respectfully submitted,

Andrea E. Dorigo

Attorney for Applicant(s)

Reg. No. 47,532

Pfizer Inc Patent Department, 5th Floor 150 East 42nd Street New York, NY 10017-5755 (212)573 -1898

| INFORMATION DISCLOSURE CITATION | | | | | | | ATTY. DOCKET NO. PC10148A | | | | | SERIAL NO. 09/834,477 | | |
|---|--|---|-----|--------|-------|---------|---------------------------|-------------|--------------|-----------------------------|------------|-----------------------|---|--|
| (Use several sheets if necessary) | | | | | | | APPLICANT A. A. Fossa | | | | | | | |
| OIR: | | | | | | FIL | FILING DATE 4/13/01 GRO | | | | | GROUP 1653 | | |
| 06 | | | | | | | U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL MAR 1 5 2001 GOCUMENT NU | | | | | | | ER | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPRO PRIATE | |
| | | 5 | . 4 | 6 | 4 | 8 | 4 | 7 | 11/7/95 | Courte- manche et al. | 514 | 342 | | |
| | | 5 | 8 | 2 | 1 | 2 | 5 | 5 | 10/13/ 98 | Roger et al. | 514 | · 342 | | |
| | | 5 | 8 | 8 | 0 | 1 | 3 | 5 | 3/9/99 | Gully et al. | 514 | 307 | | |
| | | 6 | 1 | 8 | 7 | 7 | 8 | 1 | 2/13/01 | Naka- zato et al. | 514 | 275 | | |
| | | 6 | 4 | 2 | 0 | 4 | 0 | 9 | 7/16/02 | Yama- saki et al. | 514 | 394 | | |
| | | 5 | 6 | 0 | 2 | 1 | 3 | 2 | 2/11/97 | Roger et al. | 514 | 252 | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | | |
| DOCUMENT NUMBER | | | | | | | 1 1 | | DATE | COUNTRY | CLASS | _ | TRANSLATION | |
| | | | | | | | | | | | | | | |
| | | | ОТ | HER DO | CUMEN | TS (Inc | luding Au | ıthor, Titl | e, Date, Pe | rtinent Pag | ges, Etc.) | | | |
| English language Abstract of WO98/29397 | | | | | | | | | | | | | | |
| EXAMINER DATE CONSIDERED | | | | | | | | | | | | | | |
| | EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | | |

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE